Amikacin, ethambutol, and rifampin for treatment of disseminated Mycobacterium avium-intracellulare infections in patients with acquired immune deficiency syndrome. NLM AIDSLINE Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Amikacin, ethambutol, and rifampin for treatment of disseminated Mycobacterium avium-intracellulare infections in patients with acquired immune deficiency syndrome.

Diagn Microbiol Infect Dis. 1986 Sep;5(3):215-20. Unique Identifier : AIDSLINE MED/87003435
Baron EJ; Young LS

Abstract: Synergistic combinations of achievable serum levels of amikacin, rifampin, and ethambutol were tested for their ability to inhibit growth of Mycobacterium avium-intracellulare strains isolated from seven patients with acquired immune deficiency syndrome. Even when the isolates were very resistant to the individual antimicrobial agents in vitro, growth was completely inhibited by all combinations of the three agents tested. Four of the patients treated with a combined regimen of amikacin, rifampin, and ethambutol showed clinical improvement. Synergistic antimicrobial susceptibility tests seem to more accurately represent the efficacy of combined regimens used to treat these extremely resistant mycobacteria than do conventional susceptibility determinations with individual antimicrobial agents.
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Amikacin/PHARMACOLOGY/*THERAPEUTIC USE Drug Synergism Drug Therapy, Combination Ethambutol/PHARMACOLOGY/*THERAPEUTIC USE Human Microbial Sensitivity Tests Mycobacterium avium/DRUG EFFECTS Rifampin/PHARMACOLOGY/*THERAPEUTIC USE Support, Non-U.S. Gov't Tuberculosis/COMPLICATIONS/*DRUG THERAPY JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/complicationsamikacin/pharmacology/KWDtherapeuticusedrugsynergismdrugtherapy,combinationethambutol/pharmacology/KWDtherapeuticusehumanmicrobialsensitivitytestsmycobacteriumavium/drugeffectsrifampin/pharmacology/KWDtherapeuticusesupport,non-uKWDsKWDgov'ttuberculosis/complications/KWDdrugtherapyjournalarticle
870130
M8710238

Copyright © 1987 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .